News coverage about Pacira Pharmaceuticals (NASDAQ:PCRX) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2703242295761 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Theravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head Survey (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 Shares (americanbankingnews.com)
- Pacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to Hold (americanbankingnews.com)
- WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures (finance.yahoo.com)
- WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize … – GlobeNewswire (press release) (globenewswire.com)
A number of equities research analysts have weighed in on PCRX shares. Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 9th. Bank of America decreased their price target on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, October 4th. Janney Montgomery Scott downgraded shares of Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price target on the stock. in a research note on Thursday, October 26th. Royal Bank of Canada reiterated a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, October 13th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $55.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $49.00.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $41.50 on Friday. Pacira Pharmaceuticals has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. During the same quarter in the previous year, the company earned $0.20 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. research analysts expect that Pacira Pharmaceuticals will post -0.85 EPS for the current year.
In other news, CEO David M. Stack sold 58,885 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the sale, the chief executive officer now owns 159,164 shares in the company, valued at approximately $6,102,347.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Kronenfeld bought 1,000 shares of Pacira Pharmaceuticals stock in a transaction dated Friday, November 10th. The stock was purchased at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the purchase, the director now directly owns 6,795 shares in the company, valued at approximately $282,672. The disclosure for this purchase can be found here. Insiders sold a total of 98,960 shares of company stock worth $3,868,341 in the last 90 days. 6.60% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/pacira-pharmaceuticals-pcrx-earning-somewhat-positive-press-coverage-analysis-finds.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.